{
    "id": 3250,
    "fullName": "EGFR D770_N771insG",
    "impact": "insertion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EGFR D770_N771insG results in the insertion of a glycine (G) in the protein kinase domain of the Egfr protein between amino acids 770 and 771 (UniProt.org). D770_N771insG has not been biochemically characterized, but is predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 16187797).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 410,
                    "pubMedId": 16187797,
                    "title": "Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16187797"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "D770_N771insG",
    "createDate": "02/20/2015",
    "updateDate": "09/10/2018",
    "referenceTranscriptCoordinates": {
        "id": 135565,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55181319_55181320insGGT",
        "cDna": "c.2310_2311insGGT",
        "protein": "p.D770_N771insG",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19402,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) inhibited viability of a transformed cell line expressing EGFR D770_N771insG in culture (PMID: 31467113).",
            "molecularProfile": {
                "id": 3069,
                "profileName": "EGFR D770_N771insG"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16160,
                    "pubMedId": 31467113,
                    "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31467113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19364,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed cell line expressing EGFR D770_N771insG was resistant to Tarceva (erlotinib) in culture (PMID: 31467113).",
            "molecularProfile": {
                "id": 3069,
                "profileName": "EGFR D770_N771insG"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16160,
                    "pubMedId": 31467113,
                    "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31467113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17638,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Tagrisso (osimertinib) treatment resulted in a partial response with a progression-free survival of 6.4 months in a patient with non-small cell lung cancer harboring EGFR D770_N771insG (PMID: 31208370).",
            "molecularProfile": {
                "id": 3069,
                "profileName": "EGFR D770_N771insG"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15706,
                    "pubMedId": 31208370,
                    "title": "EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31208370"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14800,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Poziotinib (HM781-36B) resulted in objective partial responses in 64% (7/11) of patients with non-small cell lung cancer harboring EGFR exon 20 mutations, including a patient with EGFR D770delinsGY (PMID: 29686424; NCT03066206).",
            "molecularProfile": {
                "id": 3069,
                "profileName": "EGFR D770_N771insG"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11486,
                    "pubMedId": 29686424,
                    "title": "Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29686424"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19358,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited viability of a transformed cell line expressing EGFR D770_N771insG in culture (PMID: 31467113).",
            "molecularProfile": {
                "id": 3069,
                "profileName": "EGFR D770_N771insG"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16160,
                    "pubMedId": 31467113,
                    "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31467113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14037,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited EGFR phosphorylation and proliferation of cells expressing EGFR exon 20 insertion mutations, including EGFR D770_N771insG, in culture (PMID: 29748209).",
            "molecularProfile": {
                "id": 3069,
                "profileName": "EGFR D770_N771insG"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11432,
                    "pubMedId": 29748209,
                    "title": "TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748209"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3069,
            "profileName": "EGFR D770_N771insG",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135565,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55181319_55181320insGGT",
            "cDna": "c.2310_2311insGGT",
            "protein": "p.D770_N771insG",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}